ImClone Receives Payment From Merck KGaA For Changes To Erbitux Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
ImClone consented to Merck’s sublicense of certain IP rights relating to anti-EGFR antibody technology to Takeda.